Xilio Therapeutics, Inc (XLO) insider trading
Every open-market stock purchase and sale by Xilio Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $2M over the last 12 months (2 buys).
- Insiders sold $5.7K over the last 12 months (2 sales).
- Last insider buy: James Samuel Shannon (Insider), $44K, 6 months ago.
Last 12 months: insiders bought $2M (2 buys) and sold $5.7K (2 sales). Last close $7.68 on Jun 7, 2026.
Recent XLO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 11, 2026 | Sara Bonstein (Insider) | Bought (not open market) | — |
| Jun 11, 2026 | James Samuel Shannon (Insider) | Bought (not open market) | — |
| Jun 11, 2026 | Robert W. Ross (Insider) | Bought (not open market) | — |
| Jun 11, 2026 | Daniel J. Curran (Insider) | Bought (not open market) | — |
| Jun 11, 2026 | Aoife Brennan (Insider) | Bought (not open market) | — |
| Jun 11, 2026 | Akintunde Olatokumbo Bello (Insider) | Bought (not open market) | — |
| Jun 11, 2026 | Yuan Xu (Insider) | Bought (not open market) | — |
| Apr 15, 2026 | Cheryl R Blanchard (Insider) | Bought (not open market) | — |
| Mar 26, 2026 | James Samuel Shannon (Insider) | Bought | $44K |
| Feb 13, 2026 | Gilead Sciences Inc. (10% owner) | Bought | $2M |
| Jan 2, 2026 | Christopher James Frankenfield (CFO) | Sold | $4.5K |
| Jan 2, 2026 | Kevin M. Brennan (VP) | Sold | $1.2K |
| Jan 1, 2026 | Christopher James Frankenfield (CFO) | Bought (not open market) | — |
| Jan 1, 2026 | Katarina Luptakova (C-suite exec) | Bought (not open market) | — |
| Jan 1, 2026 | Kevin M. Brennan (VP) | Bought (not open market) | — |
| Jan 1, 2026 | Rene Russo (CEO) | Bought (not open market) | — |
| Dec 31, 2025 | Rene Russo (CEO) | Bought (not open market) | — |
| Dec 31, 2025 | Katarina Luptakova (C-suite exec) | Bought (not open market) | — |
| Dec 31, 2025 | Kevin M. Brennan (VP) | Bought (not open market) | — |
| Dec 31, 2025 | Christopher James Frankenfield (CFO) | Bought (not open market) | — |
| Nov 26, 2025 | Gilead Sciences Inc. (10% owner) | Bought (not open market) | — |
| Nov 21, 2025 | Rene Russo (CEO) | Sold (not open market) | $2.8M |
| Nov 21, 2025 | Rene Russo (CEO) | Sold (not open market) | $1.9M |
| Nov 21, 2025 | Rene Russo (CEO) | Sold (not open market) | $1.9M |
| Nov 21, 2025 | Rene Russo (CEO) | Sold (not open market) | $1.6M |
Who's trading XLO
- James Samuel Shannon, Insider: bought $44K (1 buy), last Jun 11, 2026
- Robert W. Ross, Insider: other filings, last Jun 11, 2026
- Yuan Xu, Insider: other filings, last Jun 11, 2026
- Daniel J. Curran, Insider: other filings, last Jun 11, 2026
- Sara Bonstein, Insider: other filings, last Jun 11, 2026
- Aoife Brennan, Insider: other filings, last Jun 11, 2026
- Akintunde Olatokumbo Bello, Insider: other filings, last Jun 11, 2026
- Cheryl R Blanchard, Insider: other filings, last Apr 15, 2026
- Gilead Sciences Inc., 10% owner: bought $2M (1 buy), last Feb 13, 2026
- Christopher James Frankenfield, CFO: sold $4.5K (1 sale), last Jan 2, 2026
- Kevin M. Brennan, VP: sold $1.2K (1 sale), last Jan 2, 2026
- Katarina Luptakova, C-suite exec: other filings, last Jan 1, 2026
- Rene Russo, CEO: other filings, last Jan 1, 2026
Get free alerts when an insider at Xilio Therapeutics, Inc files a new trade →